549 related articles for article (PubMed ID: 16682403)
1. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction.
Andersen CY; Humaidan P; Ejdrup HB; Bungum L; Grøndahl ML; Westergaard LG
Hum Reprod; 2006 Aug; 21(8):2126-30. PubMed ID: 16682403
[TBL] [Abstract][Full Text] [Related]
2. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
4. Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization.
Fornaro F; Cobellis L; Mele D; Tassou A; Badolati B; Sorrentino S; De Lucia D; Colacurci N
Fertil Steril; 2007 Jan; 87(1):39-47. PubMed ID: 17084393
[TBL] [Abstract][Full Text] [Related]
5. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
6. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
7. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
[TBL] [Abstract][Full Text] [Related]
8. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
Smitz J; Andersen AN; Devroey P; Arce JC;
Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
[TBL] [Abstract][Full Text] [Related]
9. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
Pirard C; Donnez J; Loumaye E
Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
[TBL] [Abstract][Full Text] [Related]
10. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
[TBL] [Abstract][Full Text] [Related]
11. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
12. Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial.
Lossl K; Andersen CY; Loft A; Freiesleben NL; Bangsbøll S; Andersen AN
Hum Reprod; 2008 Aug; 23(8):1820-9. PubMed ID: 18487212
[TBL] [Abstract][Full Text] [Related]
13. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
[TBL] [Abstract][Full Text] [Related]
14. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin.
Pirard C; Donnez J; Loumaye E
Hum Reprod; 2005 Jul; 20(7):1798-804. PubMed ID: 15890740
[TBL] [Abstract][Full Text] [Related]
15. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study.
Blockeel C; De Vos M; Verpoest W; Stoop D; Haentjens P; Devroey P
Hum Reprod; 2009 Nov; 24(11):2910-6. PubMed ID: 19617207
[TBL] [Abstract][Full Text] [Related]
16. [Role of follicular fluid analysis in assessment of the main criteria of folliculogenesis in IVF program].
Tsagareishvili GG
Georgian Med News; 2005 Feb; (119):18-23. PubMed ID: 15834173
[TBL] [Abstract][Full Text] [Related]
17. GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Engmann L; Benadiva C
Hum Reprod; 2005 Nov; 20(11):3258-60; author reply 3260. PubMed ID: 16246862
[No Abstract] [Full Text] [Related]
18. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development.
Lainas TG; Petsas GK; Zorzovilis IZ; Iliadis GS; Lainas GT; Cazlaris HE; Kolibianakis EM
Hum Reprod; 2007 Jun; 22(6):1540-6. PubMed ID: 17347165
[TBL] [Abstract][Full Text] [Related]
19. Endocrine modifications associated with final oocyte maturation with gonadotropin-releasing hormone agonists vs. human chorionic gonadotropin in women undergoing intrauterine insemination.
Díaz I; Guillén A; Pacheco A; Requena A; Garcia-Velasco JA
J Reprod Med; 2008 Jan; 53(1):33-9. PubMed ID: 18251359
[TBL] [Abstract][Full Text] [Related]
20. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
